Skip to main content
Premium Trial:

Request an Annual Quote

Ventana to Develop CDx for Genmab Cancer Drug

NEW YORK (GenomeWeb News) – Roche business Ventana today announced a companion diagnostic development deal for a Genmab antibody drug conjugate program.

Ventana will develop an immunohistochemistry CDx test for detecting tissue factor in patient tumor samples with the intent that the assay could be used as the screening test in clinical trials for Genmab's HuMax-TF-ADC, Ventana said.

HuMax-TF-ADC is being developed for the treatment of solid cancers, and last summer Genmab filed an investigational new drug application with the US Food and Drug Administration to start a dose escalation trial of HuMax-TF-ADC to treat multiple solid tumors.

Financial and other terms of today's agreement were not disclosed.

The deal is the latest CDx agreement inked by Ventana, which noted that it is currently involved in more than 180 collaborations to develop and commercialize such assays. Last month, it extended an existing CDx agreement with Bayer Pharma for the drug firm's targeted therapy projects.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.